ReviewGenes2026
Non-Coding RNAs in Cancer Liquid Biopsy: From Regulatory Networks to Functional Biomarkers for Precision Oncology.
Review in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy is now an established component of precision oncology, and its clinical implementation to date has been led by cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) assays. These assays report genomic alterations, yet they may be limited by low tumor fraction, reduced shedding in early disease, and incomplete representation of dynamic tumor biology. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and emerging small or poorly annotated RNA species, provide a complementary layer because they can reflect regulatory programs, tissue injury, immune modulation, metastatic communication, and therapeutic pressure. This review explores circulating and extracellular vesicle (EV)-associated ncRNAs as functional readouts in cancer liquid biopsy. We discuss their biological origin, carrier state, biofluid context, clinical applications, analytical technologies, artificial intelligence (AI)-assisted integration, standardization barriers, and regulatory requirements. The technology discussion considers sequencing, targeted amplification, and emerging direct or polymerase chain reaction (PCR)-free strategies as complementary translational routes for reliable ncRNA measurement. We propose that ncRNAs should not be viewed as alternatives to ctDNA, but as potential functional biomarkers that can link tumor genotype, regulatory state, and clinical phenotype within integrated multi-analyte precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.